Evidence map›Paper›PMID 40026598›Full record

ReviewTransplant international : official journal of the European Society for Organ Transplantation2025

Progress in Porcine Kidney Transplantation to Non-Human Primates.

Stéphanie Le Bas-Bernardet, Gilles Blancho

Abstract readReview
In one paragraph

Review in Transplant international : official journal of the European Society for Organ Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Transplant International: Looking Back at 2025, Looking Forward to 2026.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stéphanie Le Bas-BernardetCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France.
Gilles BlanchoCHU Nantes, Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, ITUN, Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal xenotransplantation has recently made considerable progress in overcoming the barrier to its use in humans. This progress has been made possible owing to the use of preclinical pig-to-primate models. Overall, renal xenotransplantation has long been associated with lower survival rates than that of porcine hearts (mainly due to its life-sustaining nature). However, the use of the latest strains of genetically modified porcine donors, combined with progress in the control of the anti-porcine immune response and coagulation, has now enabled survival of up to 2 years. Although the pig-to-primate combination has long been considered a perfect reflection of the human situation, it has several limitations, particularly in terms of different natural anti-porcine antibodies. This fact, in association with survival prolongation, which is considered a prerequisite, has led some pioneering teams to cross the line of human application. However, use in humans will remain anecdotal, and further progress in renal xenotransplantation will be difficult to achieve without the use of non-human primates, which will remain complementary, particularly with regard to major innovations that have never been tested in humans.

Indexed as

Kidney TransplantationTransplantation, HeterologousAnimalsAnimals, Genetically ModifiedGraft RejectionGraft SurvivalHumansPrimatesSwinegenetically modified pigsimmunosuppressionkidneynonhuman primatesxenotransplantation

Identifiers

PMID40026598
PMCPMC11867791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.